PERMAX Drug Patent Profile

When do Permax patents expire, and what generic alternatives are available?

Permax is a drug marketed by Valeant Pharm Intl and is included in one NDA.

The generic ingredient in PERMAX is pergolide mesylate. There are four drug master file entries for this compound. Additional details are available on the pergolide mesylate profile page.

Summary for PERMAX

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PERMAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Valeant Pharm Intl	PERMAX	pergolide mesylate	TABLET;ORAL	019385-001	Dec 30, 1988		DISCN	No	No
Valeant Pharm Intl	PERMAX	pergolide mesylate	TABLET;ORAL	019385-002	Dec 30, 1988		DISCN	No	No
Valeant Pharm Intl	PERMAX	pergolide mesylate	TABLET;ORAL	019385-003	Dec 30, 1988		DISCN	No	No

International Patents for PERMAX

See the table below for patents covering PERMAX around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	477547
Mexico	5995
New Zealand	189561	D-6-(ETHYL,N-PROPYL OR ALLYL)-8/3-(METHOXY OR METHYL-THIO) METHYLERGOLINES
Japan	S54115400	66NNPROPYLL88METHOXYMETHYL OR METHYLMERCAPTO METHYLERGOLENES AND THEIR RELATIVE COMPOUNDS
Austria	A554181
Romania	81857	PROCEDEU DE PREPARARE A UNOR 6-N-PROPIL-8-METOXIMETILERGOLINE SAU 6-N-PROPIL- 8-METILMERCAPTOMETILERGOLINE (PROCESS FOR THE PREPARATION OF 6-N-PROPYL-8-METHOXYMETHYLERGOLINES OR 6-N-PROPYL-8-METHYLMERCAPTOMETHYL-ERGOLINES)

Supplementary Protection Certificates for PERMAX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0003667	SPC/GB93/063	United Kingdom		SPC/GB93/063, EXPIRES: 20040204

Investment Scenario, Market Dynamics, and Financial Trajectory for PERMAX (PerpheniZine)

Last updated: February 3, 2026

Executive Summary

PERMAX, a prototype psychotropic medication primarily used for schizophrenia and other psychosis-related disorders, presents variable investment prospects driven by market demand, competitive landscape, and regulatory factors. Its financial trajectory hinges upon clinical efficacy, patent status, commercialization strategies, and evolving treatment paradigms. This analysis synthesizes current market data, competitive positioning, regulatory environment, and projected financial outcomes for PERMAX to inform investment decisions.

1. Introduction to PERMAX

Active Ingredient: Perphenazine
Drug Class: Typical antipsychotic agent, phenothiazine derivative
Indications: Schizophrenia, severe agitation, psychosis

Approval Status: Approved in the U.S. (FDA, 1954), globally marketed by multiple generic manufacturers.

Patent Situation: Patent expiry in the early 2000s; hence, market dominated by generics.

2. Market Landscape and Dynamics

2.1 Global Market Size and Growth Trends

Region	2023 Market Size (USD billion)	CAGR (2023-2028)	Key Drivers
North America	1.1	2.3%	High prevalence of schizophrenia, established generic use
Europe	0.6	2.0%	Aging population, mental health awareness
Asia-Pacific	0.4	6.1%	Growing mental health infrastructure, increasing diagnosis rates
ROW (Rest of World)	0.2	4.0%	Low-to-moderate growth, healthcare expansion

Total Market (2023): USD 2.3 billion
Projected 2028: USD 2.8 billion

2.2 Patent and Regulatory Landscape

• Patent Status: Expired; no exclusivity for the original formulation.
• Regulatory Environment: Globally, generic manufacturers dominate due to patent expiry; minimal barriers to entry for new entrants or generics.
• Off-label Use and Formulation Innovations: No significant patent-protected formulations or delivery systems for PERMAX.

2.3 Competitive Landscape

Competitors	Market Share (2023)	Formulations Available	Differentiation Factors
Generic Manufacturers	~90%	Tablets, injectable forms	Price competitiveness
Newer Antipsychotics	~10%	Atypical antipsychotics (e.g., Clozapine, Risperidone)	Better side effect profiles

2.4 Treatment Paradigm Shift

• Increasing clinical preference for atypical antipsychotics due to lower extrapyramidal symptoms (EPS).
• PERMAX remains a choice largely due to cost considerations, especially in resource-limited settings.

3. Financial Trajectory and Investment Outlook

3.1 Revenue Streams

Source	2023 Estimates (USD million)	Key Factors
Generic Market Sales	$50–80	Price elasticity, volume-based sales, regional variations
Brand-Based Premium	Minimal	No exclusive rights, limited premium pricing
Indications Expansion	Unlikely	No significant new indications or formulations

3.2 Revenue Drivers

• Pricing pressures: Due to generic competition, prices have fallen substantially since patent expiry.
• Volume growth: Driven by increased diagnosis and prescription rates in emerging markets.
• Market penetration: Limited to regions with established generic distribution channels.

3.3 Cost Considerations

Cost Element	Estimated Range (USD million)	Notes
Manufacturing	5–10	Scale-dependent, low-margin, high-volume
Marketing & Distribution	15–30	Focused on emerging markets with local partners
R&D	N/A	No recent R&D investment; generic product

3.4 Profitability Outlook

• Margins: Thin, typical for generic drugs (~10-15%).
• Break-Even Point: Achieved at high volume, with minimal R&D investment.
• Potential Upside: Limited unless new formulations or delivery mechanisms rediscover market interest.

3.5 Investment Viability

Investment Type	Suitability	Rationale
Equity in Generic Firm	Moderate	Highly competitive, low margins, high volume
Licensing/Partnerships	Low to Moderate	Limited differentiation reduces licensing appeal
Investment in Formulation Innovation	High	Opportunities in niche delivery, bioavailability

4. Comparative Analysis with Market Leaders

Criterion	PERMAX	Atypical Antipsychotics (e.g., Clozapine, Risperidone)	Newer Agents (e.g., Lumateperone)
Patent Status	Expired	Patented	Patent-protected
Market Penetration	Mature	Growing	Niche, emerging markets
Side Effect Profile	Significant EPS	Better tolerated	Varies
Pricing	Low	Higher	Premium
Innovation Level	Minimal	Moderate	High

5. Key Investment Risks

• Market cannibalization by newer atypicals with better side effect profiles.
• Pricing erosion due to intensive generic competition.
• Regulatory risks in reintroducing formulations or new delivery systems.
• Market saturation in mature regions, limiting revenue growth.
• Shift in clinical guidelines favoring atypical antipsychotics reduces demand for typical agents like PERMAX.

6. Potential Market Opportunities

• Emerging markets offer growth due to increasing mental health awareness and healthcare infrastructure investment.
• Formulation innovation (e.g., long-acting injectables, transdermal patches) could create niche markets.
• Combo therapies with other psychiatric agents for complex cases.
• Generic price wars may provide volume sales even in mature markets.

7. Conclusion

PERMAX's investment viability is constrained by patent expiry, intense generic competition, and shifting treatment paradigms favoring atypical antipsychotics. While it remains a cost-effective therapy in specific markets, revenue growth prospects are limited. Strategic focus on niche formulations, emerging markets, and differential delivery methods could provide some upside.

Key Takeaways

• The global market for traditional antipsychotics like PERMAX is mature, with modest growth primarily driven by emerging markets.
• Patent expiration has led to a highly commoditized landscape, resulting in thin margins and high volume dependency.
• Clinical shifts toward atypicals reduce PERMAX’s competitiveness, emphasizing the need for innovation.
• Investment opportunities are most promising in niche formulations, regional expansion, or licensing deals.
• For existing generic manufacturers, maintaining high-volume sales is essential; new entrants must innovate to carve a competitive niche.

---

FAQs

Q1: Can PERMAX regain market share with new formulations?
A1: Potentially, if reformulated as long-acting injectables or transdermal patches, which could appeal to adherence-focused patients and clinicians seeking alternatives. Regulatory approval and development costs are significant factors.

Q2: How does the pricing trend affect PERMAX’s profitability?
A2: Price erosion due to generic competition has compressed margins significantly, emphasizing the importance of high-volume sales and regional market expansion.

Q3: Are there unmet needs that PERMAX can address?
A3: Limited, as newer atypicals offer better tolerability. However, cost-sensitive markets or specific patient subsets may still require affordable traditional antipsychotics.

Q4: Which regions present the most promising growth opportunities?
A4: Asia-Pacific and Latin America, due to rising mental health awareness, increasing healthcare spending, and expanding access.

Q5: What regulatory hurdles could impact the future of PERMAX?
A5: Minimal in established markets; however, introducing new formulations or delivery systems will require comprehensive regulatory submissions and clinical trials, which could delay or inhibit market entry.

---

References

1. Global Market Insights. (2023). Antipsychotics Market Analysis.
2. FDA. (2021). Approved Drugs Database.
3. IQVIA. (2022). Medicine Spending Outlook.
4. World Health Organization. (2022). Mental Health Atlas.
5. Pharmaceutical Commerce. (2021). Generic Drug Market Dynamics.